Table 2.
Description of COVID-19 outcomes according to different study groups.
| Severity/Outcome | Overall (n = 1883) | Anti-IL6 group (n = 73) | Non-Anti-IL6 group (n = 1810) | Any non-anti-IL6 biotherapy (n = 854) | Any non-anti-IL6 except rituximab (n = 754) | rituximab (n = 100) | Anti-TNF (n = 535) |
|---|---|---|---|---|---|---|---|
| Severity | |||||||
| Mild | 1263 (67.1) | 61 (83.6) | 1202 (66.4) | 644 (75.4) | 606 (80.4) | 38 (38.0) | 454 (84.9) |
| Moderate | 410 (21.8) | 7 (9.6) | 403 (22.3) | 140 (16.4) | 108 (14.3) | 32 (32.0) | 65 (12.1) |
| Severe | 210 (11.1) | 5 (6.8) | 205 (11.3) | 70 (8.2) | 40 (5.3) | 30 (30.0) | 16 (3.0) |
| Outcomea | |||||||
| Recovery without sequelae | 1353 (75.8) | 56 (80.0) | 1297 (75.6) | 637 (77.9) | 582 (80.5) | 55 (57.9) | 422 (81.6) |
| Recovery with sequelae | 317 (17.8) | 12 (17.1) | 305 (17.8) | 149 (18.2) | 127 (17.6) | 22 (23.2) | 90 (17.4) |
| Death | 115 (6.4) | 2 (2.9) | 113 (6.6) | 32 (3.9) | 14 (1.9) | 18 (18.9) | 5 (1.0) |
Values are presented as frequency (percentage).
a
98 missing values for outcome.